PacBio Files 8-K on Operations and Financials
Ticker: PACB · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1299130
Sentiment: neutral
Topics: operations, financials, sec-filing
Related Tickers: PACB
TL;DR
PacBio dropped an 8-K on Jan 14th covering ops and financials. No big news yet.
AI Summary
On January 14, 2025, Pacific Biosciences of California, Inc. (PacBio) filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with other events and financial statements. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates PacBio is providing updates on its operational and financial status to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for reporting operational and financial information, not indicating any immediate or significant new risks.
Key Players & Entities
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (company) — Registrant
- PacBio (company) — Commonly known name for the registrant
- January 14, 2025 (date) — Date of report
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided excerpt of the 8-K filing does not detail specific financial results or operational updates; it only indicates that the filing pertains to 'Results of Operations and Financial Condition'.
What is the primary purpose of this 8-K filing for Pacific Biosciences of California, Inc.?
The primary purpose of this 8-K filing is to report on the company's results of operations and financial condition, as well as other events and financial statements.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on January 14, 2025.
What is the state of incorporation for Pacific Biosciences of California, Inc.?
Pacific Biosciences of California, Inc. is incorporated in Delaware.
What is the principal executive office address for Pacific Biosciences of California, Inc.?
The principal executive office address for Pacific Biosciences of California, Inc. is 1305 O'Brien Drive, Menlo Park, California 94025.
Filing Stats: 792 words · 3 min read · ~3 pages · Grade level 11.8 · Accepted 2025-01-14 09:10:53
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market
Filing Documents
- pacb-20250114.htm (8-K) — 26KB
- exhibit991-pressrelease011.htm (EX-99.1) — 18KB
- 0001299130-25-000011.txt ( ) — 182KB
- pacb-20250114.xsd (EX-101.SCH) — 2KB
- pacb-20250114_def.xml (EX-101.DEF) — 3KB
- pacb-20250114_lab.xml (EX-101.LAB) — 23KB
- pacb-20250114_pre.xml (EX-101.PRE) — 14KB
- pacb-20250114_htm.xml (XML) — 3KB
02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On January 14, 2025, Pacific Biosciences of California, Inc. (the "Company") issued a press release providing a business update and announcing certain unaudited preliminary financial results as of and for the quarter and year ended December 31, 2024 (the "Press Release"). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information in Item 2.02 of this Current Report on Form 8-K, including the sections of the Press Release incorporated by reference herein, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. OTHER EVENTS
ITEM 8.01. OTHER EVENTS. The information set forth in the Press Release, solely to the extent such information references the Company's expectations for preliminary revenue estimates for the quarter and year ended December 31, 2024 and preliminary cash, cash equivalents and investments balance as of December 31, 2024, together with the paragraph set forth under the heading "Forward-looking statements", is incorporated by reference into Item 8.01 of this Current Report on Form 8-K. The portions of the Press Release incorporated by reference into Item 8.01 of this Current Report on Form 8-K are being filed pursuant to Item 8.01. The remaining portions of the Press Release are being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Because the Company's financial statements as of and for the quarter and year ended December 31, 2024 have not yet been finalized or audited and remain subject to change, the Company's final results for such periods may differ materially from the unaudited preliminary financial information included in the Press Release. Accordingly, you should not place undue reliance on the unaudited preliminary financial information included in the Press Release.
01. FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. 99.1 Press Release issued by Pacific Biosciences of California, Inc. dated January 14 , 202 5 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pacific Biosciences of California, Inc. By: /s/ Michele Farmer Michele Farmer Vice President and Chief Accounting Officer Date: January 14, 2025